Default company panoramic image
9992ac59 b5ff 425b a397 71f7a562fba4

Atterocor, Inc.

Atterocor is a biopharmaceutical company focused on treatments for two specific adrenal disorders with significant unmet medical needs.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Ann Arbor, MI, USA
  • Currency USD
  • Founded January 2012
  • Employees 3

Company Summary

Atterocor, Inc. is focused on developing therapies for two distinct adrenal diseases, adrenocortical carcinoma and Cushing’s syndrome. The company’s lead compound, PDX, is in late preclinical development and will enter clinical testing in early 2013. Both diseases are serious medical conditions targeting small patient populations with very limited treatment options. This provides the opportunity for an accelerated development pathway for PDX.


  • Default avatar
    Julia C Owens
    President & Chief Executive Officer

    Dr. Owens is a biotech entrepreneur with an extensive background in venture-backed biopharma companies and particular expertise in pharmaceutical company transactions. Prior to co-founding Atterocor, she served as SVP, Corporate Development & Strategy at Lycera. Dr. Owens also held positions at QuatRx, Tularik and the UCSF OTM. Dr. Owens has a Ph.D. in biochemistry from UCSF and a B.S. in chemistry and B.A. in MCB from UC Berkeley.

  • Default avatar
    Raili Kerppola
    Chief Operating Officer

    Dr. Kerppola is an experienced life sciences professional with skills in business development, strategy, marketing, and economic analysis. In addition to Atterocor, she is CEO of ONL Therapeutics, a pre-seed stage ophthalmic company. Dr. Kerppola previously worked at Express Scripts, Bausch & Lomb, MEDC, Parke-Davis and McKinsey. She earned her Ph.D. in Biochemistry at UC Berkeley, MBA at Columbia, and B.S. at Washington State Univ.

  • Default avatar
    Martin Phillips
    Acting Chief Medical Officer

    Dr. Phillips served for 8 years as the Chief Medical Officer & SVP Clinical Development for Morphotek, which was acquired by Eisai. He ran multiple phase I through III oncology studies globally on 4 novel compounds. Previously he was at Aventis Behring and held appointments as Assoc Prof of Medicine at Univ of Texas Med School and Assist Prof at Baylor College of Medicine. Dr. Phillips has a BS from Univ of Michigan, MD from Wayne State Univ.


  • Default avatar
    Honigman Miller Schwartz and Cohn LLP
    Default avatar
    Eric Halverson, Diag Ventures

Previous Investors

  • Default avatar
    Frazier Healthcare Ventures